Self-dissolving microneedles for the percutaneous absorption of EPO in mice

被引:117
作者
Ito, Yukako [1 ]
Yoshimitsu, Jun-Ichiro [1 ]
Shiroyama, Keiji [1 ]
Sugioka, Nobuyuki [1 ]
Takada, Kanji [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078414, Japan
关键词
microneedle; EPO; percutaneous absorption; mice;
D O I
10.1080/10611860600785080
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Erythropoietin (EPO) loaded microneedles were prepared using thread-forming polymer as a base for the percutaneous administration of EPO. The used polymers were dextrin, chondroitin sulfate and albumin. Under room temperature, EPO solution was added to high concentration of polymer solution and microneedles were prepared by forming thread with polypropylene tips. The mean weight of microneedle was 0.59 +/- 0.01 mg and length and basal diameter were 3.24 +/- 0.16 and 0.55 +/- 0.03 mm, respectively. Four microneedles were percutaneously (pc) administered to mice at the EPO dose levels of 100 IU/kg. After administration, blood samples were collected for 24 h and serum EPO levels were measured. Dextrin EPO microneedles were administered both pc and subcutaneously (sc) to mice. Serum EPO levels vs. time profiles showed C-max of 138.6 +/- 16.1 and 146.5 +/- 8.0 mIU/ml, respectively. T-max were 7.5 h. The values of bioavailability (BA) of EPO were 82.1 and 99.4%, respectively. By decreasing the dose from 100 to 50 and 25 IU/kg, dose-dependent serum EPO levels vs. time profiles were not clearly obtained. When chondroitin sulfate and albumin were used as the microneedle base, the serum EPO levels vs. time profiles showed almost the same pattern. Cmax of chondroitin sulfate and albumin microneedles were 96.3 +/- 8.8 and 132.2 +/- 18.9 mIU/ml, respectively. AUCs were 835.1 and 1098.7 mIU h/ml. T-max were 8 and 6.8 h. These results suggest the usefulness of microneedles for the percutaneous administration of EPO.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 46 条
[1]   ERYTHROPOIETIN FOR ANEMIA IN CANCER-PATIENTS [J].
ABELS, R .
EUROPEAN JOURNAL OF CANCER, 1993, 29A :S2-S8
[2]   Bioabsorbable implants: Review of clinical experience in orthopedic surgery [J].
Ambrose, CG ;
Clanton, TO .
ANNALS OF BIOMEDICAL ENGINEERING, 2004, 32 (01) :171-177
[3]  
AMINO Y, 1988, CHEM PHARM BULL, V36, P4426
[4]   Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice [J].
Bleuel, H ;
Hoffmann, R ;
Kaufmann, B ;
Neubert, P ;
Ochlich, PP ;
Schaumann, W .
PHARMACOLOGY, 1996, 52 (05) :329-338
[5]   RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY FOR ANEMIC CANCER-PATIENTS ON COMBINATION CHEMOTHERAPY [J].
CASE, DC ;
BUKOWSKI, RM ;
CAREY, RW ;
FISHKIN, EH ;
HENRY, DH ;
JACOBSON, RJ ;
JONES, SE ;
KELLER, AM ;
KUGLER, JW ;
NICHOLS, CR ;
SALMON, SE ;
SILVER, RT ;
STORNIOLO, AM ;
WAMPLER, GL ;
DOOLEY, CM ;
LARHOLT, KM ;
NELSON, RA ;
ABELS, RI .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :801-806
[6]   Lipid vesicles and other colloids as drug carriers on the skin [J].
Cevc, G .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (05) :675-711
[7]   Surface micromachined metallic microneedles [J].
Chandrasekaran, S ;
Brazzle, JD ;
Frazier, AB .
JOURNAL OF MICROELECTROMECHANICAL SYSTEMS, 2003, 12 (03) :281-288
[8]   Insulin in w/o/w multiple emulsions: Biological activity after oral administration in normal and diabetic rats [J].
Cunha, AS ;
Grossiord, JL ;
Puisieux, F ;
Seiller, M .
JOURNAL OF MICROENCAPSULATION, 1997, 14 (03) :321-333
[9]   CHARACTERIZATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN PRODUCED IN CHINESE-HAMSTER OVARY CELLS [J].
DAVIS, JM ;
ARAKAWA, T ;
STRICKLAND, TW ;
YPHANTIS, DA .
BIOCHEMISTRY, 1987, 26 (09) :2633-2638
[10]   Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study [J].
Demetri, GD ;
Kris, M ;
Wade, J ;
Degos, L ;
Cella, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3412-3425